Quotes

From time to time, Magnifina staff makes quotes to the media. Below is a list of known usages and the original context with which the quote was given. Some quotes are altered with permission, while others are altered without permission.

2020-11-17

https://www.zolo.ca/blog/best-financial-tips-for-generations

“It’s never too soon or too late to invest in the stock market. Young investors may feel apprehensive because they are waiting for a good deal when markets fall. The truth is, it’s impossible to time the market perfectly. A strategy to avoid missing out, is to invest a set amount every month whether markets are up or down and to be disciplined about it. Young investors have the benefit of time, and the stock market usually makes new highs within years of a previous top”

2020-11-13

https://www.businessinsider.com/how-to-invest-in-penny-stocks

Quote altered with permission

“There aren’t many success stories about investing in penny stocks. Their appeal is understandable: perhaps there is some company trading at pennies which may increase in value by 10x or more. However, this is exceedingly rare and the old wisdom about “too good to be true” often applies. Investors are also drawn to penny stocks because they appear more affordable. Now that several brokers offer fractional share trading, there’s no good reason to pick stocks simply because of the single share price.

Looking at a stock’s market cap (i.e. the total price of all the shares) is more helpful. It might be better to think of “penny stocks” as “microcap” stocks instead. When analysing these companies, it’s important to figure out the reasons behind a company’s value. For most microcap stocks I’ve looked at, the company went public but its business eroded until just the corporate entity remains. These “zombie companies” have some value in that they are already listed on exchanges. Private companies looking to go public may avoid the costs of an IPO through something called a “reverse takeover”. This is especially popular with foreign companies looking to list themselves on US exchanges.

Nevertheless, there is still significant value in analyzing microcap stocks to search for genuinely distressed equities. These would be viable businesses which have fallen on hard times, but retain a path to recovery. Indeed, some investors specialize in identifying these rare companies and the profits can be extraordinary. A great example is Mortgage Guaranty Insurance Corporation (MTG) in 2012. Their mortgage insurance business had been decimated by the subprime mortgage crisis, and almost went bankrupt. However, the company recovered, and the stock rallied over 1000% in 5 years. MTG was only technically a penny stock for one month 2012, but it remained a microcap stock for several years. Even when the price was $2.00, it vastly outperformed countless other stocks during the same period. That’s why limiting analysis to prices below $1.00 may miss some great opportunities.”

2020-11-11

https://www.newsday.com/business/coronavirus/socially-responsible-investing-nance-nash-1.50059349

“SRI is all the rage and we’re seeing robust demand from our clients. But because it’s such a new trend, SRI remains very abstract and poorly defined. Everyone has different values, and it is difficult to measure exactly how an investment would satisfy them. One value that everyone tends to agree about is environmentalism. Renewable energy stocks have been performing well recently and more and more companies are pledging to lower the carbon emissions that result from their business. 
 
A common framework for evaluating potential investments is ESG. (Environmental, Social, and corporate Governance). Several stock research firms provide numerical ratings for ESG. The methods for rating companies are abstract and inconsistent between analysts. They tend to focus on measuring PR risks related to ESG controversies, rather than the actual impacts of each company’s business. 
 
Indeed, SRI is not a science; it is definitely more of an art. Our approach to SRI is to frame it as “Ethical Investing,” and select investments that don’t violate the client’s ethical guidelines. This means that our clients can let us know about activities and affiliations that they disagree with, and we will avoid investing in related companies for them. We rely on 3rd party research to supplement our own research for identifying controversial activities.
 
In terms of performance, we caution our clients that restricting the list of potential investments may result in lower portfolio returns. However, we appreciate that not all profit is financial, and we support considering the environmental and social impacts of investments. Nevertheless, renewable energy stocks have performed very well in 2020. ICLN is an ETF of clean energy stocks, and is up nearly 70% year-to-date. It hasn’t been this high since 2011, when oil prices were nearly $100 per barrel.”

2020-11-02

https://finance.yahoo.com/news/advice-mark-cuban-warren-buffett-130047649.html

https://www.gobankingrates.com/money/financial-planning/advice-experts-survive-crisis/

“The pandemic is certainly the biggest economic event which has occurred for many years. There was a violent market reaction in March and April. But many analysts predict that by this time next year, it will no longer be affecting the stock market. This is Buffett’s wisdom: to invest with a very very long-term horizon. He is the master at putting aside emotions, and focusing strictly on the numbers. According to our research, only 30% of bear markets since 1950 have lasted more than three and a half years. The most recent one didn’t even last three quarters.”

2020-10-22

https://investorplace.com/2020/10/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine/

https://www.nasdaq.com/articles/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine-2020-10-22

“Novavax‘s vaccine candidate will not likely be the first to market, but will stand in contrast to the mRNA vaccines by Moderna and Pfeizer. As I understand it, mRNA biotechnology allows for faster scaled production. However, it is brand-new technology which has never been used commercially in humans. The way mRNA vaccines work is scary and sounds very close to genetic engineering or editing. In contrast, Novavax uses a tried-and-true method to produce immunity. News media and social media are almost certain to hype up reports of side effects during the first round of vaccination. Vaccine hesitancy is growing, and in 2018 almost half of US citizens refused a flu vaccine. Waiting a few more months for Novavax‘s vaccine candidate would appeal to vaccine hesitant individuals who are not fully anti-vax.”
 
 

Magnifina, LLC is a Registered Investment Adviser. SEC# 801-117932. This website and information are provided for guidance and information purposes only. No historical or future performance claims are made. This website and information are not intended to provide investment, tax, or legal advice. Please consult a qualified professional before making decisions about your financial situation.